<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424122</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-112 (CITADEL-112)</org_study_id>
    <nct_id>NCT03424122</nct_id>
  </id_info>
  <brief_title>INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of INCB050465 when
      combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with
      relapsed or refractory B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">December 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 12 months.</time_frame>
    <description>A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of INCB050465 in combination with rituximab, bendamustine and rituximab, or ibrutinib</measure>
    <time_frame>Up to approximately 1 month.</time_frame>
    <description>Measured to assess the plasma pharmacokinetic profile of INCB050465 in combination with rituximab, bendamustine and rituximab, and ibrutinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of INCB050465 in combination with rituximab, bendamustine and rituximab, or ibrutinib</measure>
    <time_frame>Up to approximately 1 month.</time_frame>
    <description>Measured to assess the plasma pharmacokinetic profile of INCB050465 in combination with rituximab, bendamustine and rituximab, and ibrutinib.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB050465 + Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB050465 + Bendamustine + Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB050465 + Ibrutinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB050465</intervention_name>
    <description>INCB050465 administered orally once daily for 8 weeks followed by once weekly.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Treanda, Bendeka</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib administered orally once daily.</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.

          -  Received at least 1 prior line of systemic therapy with documented progression or
             documented failure to achieve complete response or partial response after the most
             recent systemic treatment regimen.

          -  Ineligible for stem cell transplant.

          -  Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or
             to provide a lymph node or tissue biopsy from the most recent available archival
             tissue.

          -  Life expectancy of &gt; 3 months.

          -  Eastern Cooperative Oncology Group performance status score of 0 to 2.

          -  Adequate hematologic, hepatic, and renal function (values must not be achieved with
             growth factors) per protocol-defined criteria.

          -  Willingness to avoid pregnancy or fathering children.

        Exclusion Criteria:

          -  Evidence of transformed non-Hodgkin lymphoma histologies (with the exception of FL).

          -  Histologically confirmed rare non-Hodgkin B-cell subtypes.

          -  History of or central nervous system lymphoma (either primary or metastatic) or
             leptomeningeal disease.

          -  Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K
             inhibitor.

          -  For participants to be treated with bendamustine (Treatment B), prior treatment with
             bendamustine (within 12 months of the start of study treatment). Participants with
             prior bendamustine treatment (&gt; 12 months before the start of study treatment) are
             eligible if they meet the following criteria:

               -  Did not discontinue because of tolerability concerns.

               -  Achieved either partial response (PR) or complete response (CR) to the
                  bendamustine regimen of at least 12 months in duration before
                  relapse/progression.

               -  Experienced progression following a regimen containing an alkylating agent.

          -  For participants to be treated with ibrutinib (Treatment C), prior treatment with a
             Bruton's tyrosine kinase (BTK) inhibitor.

          -  Allogeneic stem cell transplant within the last 6 months or autologous stem cell
             transplant within the last 3 months before the date of the first dose of study
             treatment.

          -  Active graft-versus-host disease following allogeneic transplant.

          -  Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Espinola, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
  <keyword>follicular lymphoma (FL)</keyword>
  <keyword>marginal zone lymphoma (MZL)</keyword>
  <keyword>mantle cell lymphoma (MCL)</keyword>
  <keyword>phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

